SCHEMBL29270535

SCHEMBL29270535

CC1(C)CN(c2nnc(-c3ccc4c(c3)N(Cc3ccc(Cl)cc3)C[C@@H](N)CS4(=O)=O)o2)CCO1

nearest known ligand 0.38

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ PIK3CD O00329 1/20 0.33
▸ PIK3CA P42336 1/20 0.33
▸ PIK3CB P42338 1/20 0.33
▸ PIK3CG P48736 1/20 0.33
▸ BACE1 P56817 2/20 0.32
▸ BACE2 Q9Y5Z0 1/20 0.32
▸ ENPP2 Q13822 1/20 0.31
▸ ATXN2 Q99700 1/20 0.31
▸ GRM2 Q14416 1/20 0.31
▸ BCHE P06276 1/20 0.31
▸ ACHE P22303 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29270569 0.91 KDM4E (0.38) KDM4ENPC1RAB9ABACE1BACE2
SCHEMBL29270547 0.88 KDM4E (0.51) KDM4ENPC1RAB9APIK3CDPIK3CB
SCHEMBL29270518 0.88 PIK3CD (0.32) KDM4ENPC1RAB9APIK3CDPIK3CA
SCHEMBL26961329 0.86 RAB9A (0.37) KDM4ENPC1RAB9APIK3CDPIK3CA
SCHEMBL29270639 0.85 KDM4E (0.38) KDM4ENPC1RAB9ABACE1BACE2
SCHEMBL29270431 0.83 KDM4E (0.37) KDM4ENPC1RAB9ABACE1BCHE
SCHEMBL29270502 0.81 S1PR1 (0.32) —
SCHEMBL29270473 0.81 KMT2A (0.42) KDM4ENPC1RAB9ABACE1BACE2
SCHEMBL29270587 0.80 HPGD (0.40) KDM4ENPC1RAB9ABACE1BACE2
SCHEMBL29270632 0.79 NPC1 (0.44) KDM4ENPC1RAB9ABACE1BACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116964048-A Bicyclic tetrahydroazepine derivatives for the treatment of cancer 豪夫迈·罗氏有限公司 2023-10-27 — — CN claimed
CN-116964048-A Bicyclic tetrahydroazepine derivatives for the treatment of cancer 豪夫迈·罗氏有限公司 2023-10-27 — — CN disclosed
Send feedback